Skip to main content

Table 3 Subgroup analysis of neoadjuvant chemoradiotherapy (NACRT) and upfront surgery patients

From: A lower cut-off for lymph node harvest predicts for poorer overall survival after rectal surgery post neoadjuvant chemoradiotherapy

Variables

Category

N

Disease-free survival

Overall survival

Median ± SD (months)

P value

Median ± SD (months)

P value

NACRT group (N= 94)

 Tumour staging

Stage 1

18

88 ± 39

0.026

88 ± 39

0.051

Stage 2

32

73 ± 40

76 ± 39

Stage 3

44

67 ± 37

74 ± 36

 Lymph node harvest

< 12

36

61 ± 38

0.801

63 ± 41

0.436

≥ 12

58

80 ± 40

86 ± 39

Upfront surgery group (N= 163)

 Tumour staging

Stage 1

43

82 ± 38

0.001

84 ± 41

0.003

Stage 2

29

61 ± 37

68 ± 40

Stage 3

91

54 ± 35

60 ± 37

 Lymph node harvest

< 12

17

61 ± 38

0.040

61 ± 39

0.013

≥ 12

146

63 ± 41

68 ± 38